Statement of Need
Pain is prevalent and costly, yet remains undertreated and poorly treated, leading to greater disability than cancer, diabetes, and heart disease combined and representing an annual economic burden of up to $635 billion in the United States alone. Clinicians cite a lack of formal education in pain management, time constraints, an inconsistent lexicon, and changing legal environment as barriers to appropriate treatment. Opioid therapies, long used as effective analgesics, are associated with serious adverse outcomes, including addiction and unintentional overdose. Misuse and abuse of these agents, resulting in injury and death, is a major public health problem. In 2009, nearly 343,000 visits to emergency departments involved nonmedical use of opioid analgesics. In 2008, nearly 14,800 Americans died from drug poisonings involving opioid analgesics. Physicians have identified opioid analgesia as one of the most complicated and worrisome responsibilities in pain management, as an inadequate understanding of issues such as risk assessment, tolerance, interpatient variability, and related phenomena may have the unintended effect of impeding patient access to pain relief. In addition, there is an urgent need for primary care physicians who are competent in pain management; currently, there is only one pain specialist for every 21,000 patients. With the recent release of an FDA Risk Evaluation and Mitigation Strategegy (REMS) in the area of opioid analgesia, it is imperative that physicians obtain education in the safe prescribing of these therapies.
Educate health care providers on REMS in the management of chronic pain using evidence-based, risk-directed strategies for optimizing pain management, in order to enhance patient care and improve outcomes.
Estimated Time for Completion
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Global Education Group and Applied Clinical Education. Global Education Group is accredited by the ACCME to provide continuing medical education for physicians.
Global Education Group designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Method of Participation
To receive CME credit, participants should read the preamble; complete the pre-test, view the webinar, and complete the post-test and activity evaluation. CME certificates will be made available immediately upon successful completion.
There are no fees for participating in or receiving credit for this activity.
Disclosure of Conflicts of Interest
Global Education Group requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest they may have as related to the content of this activity. All identified conflicts of interest are vetted thoroughly by Global Education Group for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity.
Charles E. Argoff, MD
- Consultant/Independent Contractor: Covidien, Depomed, Nuvo Research, Pfizer, Shionigi Pharm
- Grant/Research Support: Endo Pharmaceuticals, Forest Laboratories, Lilly
- Honoraria: Endo Pharmaceuticals
- Speakers' Bureaus: Depomed, Endo Pharmaceuticals, Horizon, Lilly
- Stock Shareholder: Pfizer
- Other/Royalty: Elsevier (books: Pain Management Secrets, Raj's Practical Management of Pain)
Marc R. Gerber, MD
- Speakers' Bureaus: Cephalon, Covidien, Endo, PriCara, Purdue
Bill H. McCarberg, MD, FABM
- Consultant/Independent Contractor: Endo, Insys Therapeutics, NeurogesX, Pfizer, Pricara, Purdue, QRx Pharma, Salix, Sucampo, Teva
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity.
Ashley Marostica, RN, MSN
Amanda Glazar, PhD
Kathleen Wildasin, MA
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group and Applied Clinical Education do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or courses of diagnosis or treatment discussed should not be used by clinicians without evaluation of patient conditions, contraindications, applicable manufacturer's product information, and the recommendations of other authorities.
Accreditor Contact Information
For information about the accreditation of this program, please contact Global Education Group at (303) 395-1782 or firstname.lastname@example.org.
This activity is jointly sponsored by Global Education Group and Applied Clinical Education.
This activity is supported by an educational grant from Mallinckrodt Pharmaceuticals.